Refine search

Date
Tumour Site
Topics
Congress

605 results for ""

The paradigm shift led by CDK4/6 inhibitors in breast cancer

The paradigm shift led by CDK4/6 inhibitors in breast cancer

The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm  of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.

    By
  • Carmen Criscitiello

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.